Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026?

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the champion healthcare stocks to bargain for 2026. Takeda Pharmaceutical Company Limited (NYSE:TAK) reported Q3 FY2025 results connected January 29, 2026, with gross down 3.3% year-over-year astatine changeless speech rates owed to VYVANSE’s nonaccomplishment of exclusivity. Growth and motorboat products roseate 6.7% astatine CER and present relationship for 52% of revenue, helping offset declines. Key drivers included Entyvio (+7.4%), Livtencity (+43.6%), and Qdenga (+22.1%), underscoring however caller products are cushioning the interaction of VYVANSE’s 45.7% drop.

Financially, Takeda posted Q3 YTD gross of ¥3,411.2 billion, halfway operating nett down 3.4% to ¥971.6 billion, and reported operating nett up 1.2% to ¥422.4 billion. Cash travel remained strong, with operating currency travel up 15.8% to ¥966.9 cardinal and adjusted escaped currency travel up 10.1% to ¥625.9 billion. Looking ahead, the institution is preparing to motorboat 3 transformative medicines—Oveporexton, Rusfertide, and Zasocitinib—between precocious 2026 and aboriginal 2027, portion accelerating late-stage programs successful gastrointestinal, neuroscience, and oncology to thrust semipermanent growth.

On January 22, Takeda announced the U.S. motorboat of GAMMAGARD LIQUID ERC, a ready-to-use immunoglobulin therapy for superior immunodeficiency (PI) patients aged 2 and older. The 10% solution, with IgA contented ≤2 μg/mL, tin beryllium administered intravenously oregon subcutaneously without reconstitution, easing attraction for patients and providers. Available successful 5g/50mL and 10g/100mL vials, it features Enhanced Removal Capability to little IgA levels, offers agelong support beingness astatine country somesthesia oregon refrigeration, and adds to Takeda’s wide IG portfolio. While not specifically indicated for IgA sensitivity, it whitethorn suit immoderate PI patients, though risks specified arsenic thrombosis, renal dysfunction, and hypersensitivity remain.

Takeda Pharmaceutical Company Limited (NYSE:TAK) is simply a top-20 global, R&D-driven biopharmaceutical institution headquartered successful Japan, focusing connected discovering, developing, and manufacturing innovative medicines. Key areas see oncology, uncommon diseases, neuroscience, gastroenterology (GI), plasma-derived therapies, and vaccines.

While we admit the imaginable of TAK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.